Resolvin E1 Bone Loss Prevention in Periodontal Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for periodontal diseases, such as periodontitis, are partially effective in removing bacterial accretions and often lead to transient results, with systemic antibiotics failing to maintain sufficient concentrations in the gingival crevice, and surgical interventions being necessary for advanced cases, highlighting a need for novel methods to prevent and treat bone loss associated with these diseases.
Innovation Solution
The topical administration of Resolvin E1 is shown to prevent bone loss in a rabbit model of P. gingivalis-induced periodontitis, promoting bone growth and deposition, and can be combined with therapeutic agents like bone morphogenetic factors or anti-resorptive agents to enhance bone health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If scaling and root planning are used to remove bacterial accretions, then the root surface is cleaned, but the results are transient and bacteria re-colonize quickly
Solution Approach 1:
The patent applies preliminary action by delivering antibiotics directly to the root surface before bacterial re-colonization occurs. The controlled release system pre-positions the therapeutic agent at the treatment site, creating a reservoir that releases antibiotics over time to prevent bacteria from establishing themselves again on the cleaned surface.
Solution Approach 2:
The patent implements continuity of useful action through a controlled release mechanism that maintains continuous antibiotic delivery to the gingival crevice. This sustained release ensures the therapeutic agent remains effective over an extended period, preventing bacterial re-colonization rather than providing only transient cleaning effects.
2Reliability
If systemic antibiotics are administered, then bacterial infection is treated, but insufficient concentration is maintained in the gingival crevice
Solution Approach 1:
The patent applies local quality by concentrating the antibiotic delivery specifically at the gingival crevice and root surface area where periodontal bacteria thrive. Rather than systemic distribution, the controlled release device places the therapeutic agent locally, ensuring high concentration where needed while avoiding unnecessary systemic exposure.
Solution Approach 2:
The patent uses a controlled release device as an intermediary between systemic antibiotic administration and the target bacteria. This intermediary mechanism captures and stores the antibiotic, then releases it gradually at the treatment site, bridging the gap between systemic delivery and local concentration requirements.
3Object-affected harmful factors
If surgical intervention is performed for advanced periodontal cases, then bone loss is addressed, but the treatment is invasive and complex
Solution Approach 1:
The patent applies self-service by enabling the treated tissue to continue receiving therapeutic benefits after the initial cleaning procedure. The controlled release device allows the root surface and surrounding tissues to self-treat by continuously releasing antibiotics directly at the site, reducing the need for repeated invasive surgical interventions.
Data Source
AI summary
The invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolving. In particular, the inventive methods may be useful for treating or preventing conditions associated with bone degradation, deterioration or degeneration such as periodontal disease, osteoarthritis, and metastatic bone disease and osteolytic bone disease. Pharmaceutical compositions and kits comprising at least one resolving are also provided that can be used to performed the inventive methods.